ArticleHematology reports2025

Role of Daratumumab, Lenalidomide, and Dexamethasone in Transplantation-Eligible Patients with Multiple Myeloma After the Failure of Bortezomib-Based Induction Therapy.

Shun Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.